New heart device targets dangerous rhythms in first human test
NCT ID NCT06203262
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a new device called the FieldForce™ Ablation System in 34 people with ventricular arrhythmias (dangerous heart rhythms). The device uses pulsed electric fields to destroy the small areas of heart tissue causing the problem. The main goal was to see if the procedure is safe and feasible, with a secondary focus on reducing the burden of arrhythmias.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
FieldForce™ Ablation System (pulsed field ablation device)
What this could lead to
If successful, this could provide a new, safer way to destroy abnormal heart tissue causing dangerous heart rhythms, potentially reducing symptoms and improving quality of life.
What could go wrong
This is a very early, first-in-human study with only 34 people. The device may not work as well as existing methods, and there are risks from the procedure itself, such as bleeding or damage to the heart.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENTRICULAR ARRYTHMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IKEM
Prague, Czechia
-
Na Homolce Hospital
Prague, 150 00, Czechia